Get the Stockscreener App
32.22
2.78%
0.87
Supernus Pharmaceuticals Inc stock is traded at $32.22, with a volume of 356.06K.
It is up +2.78% in the last 24 hours and down -2.51% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$31.35
Open:
$31.41
24h Volume:
356.06K
Relative Volume:
0.61
Market Cap:
$1.69B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
30.12
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+4.75%
1M Performance:
-2.51%
6M Performance:
-5.04%
1Y Performance:
+9.93%
1-Day Range:
$31.16
$32.36
1-Week Range:
$29.87
$32.36
52-Week Range:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
32.22 | 1.69B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Wells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Bank of Montreal Can Buys 473 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
3 Healthcare Stocks with Mounting Challenges - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 - The Manila Times
Supernus Pharmaceuticals, Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025 - Nasdaq
Supernus Pharmaceuticals to Announce First Quarter 2025 - GlobeNewswire
Supernus Q1 2025 Earnings Preview: CEO Jack Khattar to Detail Financial Performance May 6 - Stock Titan
Federated Hermes Inc. Has $58,000 Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Long Term Investment Analysis - news.stocktradersdaily.com
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by StockNews.com - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Franklin Resources Inc. - Defense World
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Levi & Korsinsky Reminds Shareholders of an Investigation into Supernus Pharmaceuticals, Inc. (SUPN) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Geode Capital Management LLC - Defense World
Wellington Management Group LLP Sells 2,826 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SUPN stock soars to 52-week high, hits $39.38 amid growth - MSN
Shareholders that lost money on Supernus Pharmaceuticals, Inc.(SUPN) should contact Levi & Korsinsky about Securities Fraud InvestigationSUPN - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Norges Bank Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsSUPN - ACCESS Newswire
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - The AM Reporter
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Commonwealth Equity Services LLC - Defense World
ATTENTION Supernus Pharmaceuticals, Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Vanguard Group Inc. Has $222.41 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Several Supernus Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by HighTower Advisors LLC - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to “Strong-Buy” Rating - Defense World
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses. - ACCESS Newswire
Thrivent Financial for Lutherans Sells 591 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Teacher Retirement System of Texas Has $591,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Swiss National Bank - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by StockNews.com - Defense World
11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC - Defense World
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Raymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Taking a Closer Look At Supernus Pharmaceuticals Inc (SUPN) Following Its Recent Trade - knoxdaily.com
(SUPN) Trading Report - news.stocktradersdaily.com
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment - ACCESS Newswire
PNC Financial Services Group Inc. Sells 362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Atria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround - Yahoo Finance
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
| Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
0.00%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):